Trial Profile
A study of CA4P in combination with Opdivo evaluating the combination in advanced melanoma patients who have not responded to currently approved treatments
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Fosbretabulin (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 21 May 2018 New trial record